Toremifene – a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy
- 27 February 2006
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 15 (3) , 293-305
- https://doi.org/10.1517/13543784.15.3.293
Abstract
(2006). Toremifene – a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opinion on Investigational Drugs: Vol. 15, No. 3, pp. 293-305.Keywords
This publication has 130 references indexed in Scilit:
- Gene expression changes in rat prostate after activation or blocking of the androgen and estrogen receptorMolecular and Cellular Endocrinology, 2005
- URETHRAL TUMOR RECURRENCE FOLLOWING CYSTECTOMY AND URINARY DIVERSION: CLINICAL AND PATHOLOGICAL CHARACTERISTICS IN 768 MALE PATIENTSJournal of Urology, 2005
- Effect of anti-estrogens on the androgen receptor activity and cell proliferation in prostate cancer cellsUrological Research, 2004
- Estradiol and Selective Estrogen Receptor Modulators Differentially Regulate Target Genes with Estrogen Receptors α and βMolecular Biology of the Cell, 2004
- Pathological and molecular aspects of prostate cancerThe Lancet, 2003
- The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinomaCancer, 1998
- Osteoporosis After Orchiectomy for Prostate CancerJournal of Urology, 1997
- Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancerBreast Cancer Research and Treatment, 1990
- Pharmacokinetics of toremifeneJournal of Steroid Biochemistry, 1990
- Metabolism of toremifene in the ratJournal of Steroid Biochemistry, 1990